Compare ZYME & NAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZYME | NAC |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2017 | N/A |
| Metric | ZYME | NAC |
|---|---|---|
| Price | $25.80 | $11.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $28.50 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 307.3K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.33% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,481,000.00 | N/A |
| Revenue This Year | $64.45 | N/A |
| Revenue Next Year | $67.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 116.21 | N/A |
| 52 Week Low | $9.03 | $9.32 |
| 52 Week High | $28.49 | $11.21 |
| Indicator | ZYME | NAC |
|---|---|---|
| Relative Strength Index (RSI) | 63.18 | 58.75 |
| Support Level | $24.83 | $11.85 |
| Resistance Level | $27.49 | $11.89 |
| Average True Range (ATR) | 1.32 | 0.10 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 60.00 | 93.90 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Nuveen California Quality Municipal Income Fund is a diversified closed-end management investment company. Its objective is to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal and California state income taxes. It invests majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.